In this context, an integrated model combining tumor molecular profiling (e.g., immunohistochemistry for MMR proteins, MSI status), in silico protein variant predictions (e.g., protein structure modelling, evolutionary conservation), and the identification of the same rare variant in unrelated families may provide additional insight into the pathogenicity of VUSs involving the PMS2 gene [14]. Here, PMS2 is linked to neoplasm.